Sept 30 (Reuters) – The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
* Lack of evidence poor performance rating reflected bias * No sanctions for deleted recordings,…
NOVARTIS SAYS WHOLESESALE ACQUISTION COST OF RHAPSIDO IS $4,521 PER PACKAGE (The article has been…
SEOUL, Oct 1 (Reuters) - North Korean leader Kim Jong Un told Chinese President Xi…
By Milana Vinn, Federico Maccioni and Zaheer Kachwala LONDON(Reuters) -For years, tech-focused buyout group Silver…
Sept 30 (Reuters) - Somnigroup International Inc : * SOMNIGROUP INTERNATIONAL APPOINTS NEW DIRECTOR Source…
(Reuters) -LG Electronics India is seeking a valuation of up to 774 billion rupees ($8.71…